CMCO Q4 2026 Earnings Transcript

Columbus McKinnon reported fiscal 2026 net sales of $1.2 billion, up 24%, and Q4 sales of $438 million, up 77%, driven by the Kito Crosby acquisition, pricing, and FX, but profitability was weighed by tariffs, mix, and a $200 million goodwill impairment. Adjusted EBITDA rose 93% in Q4 to $69 million with a 15.7% margin, while year-end liquidity reached $561 million and net leverage was 5.1x. Fiscal 2027 guidance calls for $2.05 billion-$2.12 billion in sales and $390 million-$410 million in adjusted EBITDA, but management flagged EMEA and Middle East demand risks plus inflationary pressure.

Analysis

The core takeaway is that CMCO is no longer a clean operating story; it’s a levered integration story with a near-term optics problem and a longer-term cash conversion setup. The market is likely still anchoring on headline GAAP noise and leverage, but the more relevant variable is whether management can convert modest organic growth plus synergies into a faster-than-expected step-down in net leverage over the next 4-8 quarters. If they do, the equity rerates on multiple expansion before earnings power fully shows up; if they don’t, the capital structure keeps the stock trapped as a low-quality cyclical.

The second-order dynamic is that pricing discipline is being used as a bridge over inflation, but that usually works with a lag and can compress demand in Europe and project-heavy end markets before it protects margin. That creates a setup where near-term results can look choppy even if the medium-term thesis improves, especially because the company’s mix is shifting toward larger, longer-cycle business that is more sensitive to order timing and shipment slippage. In other words, the downside is not catastrophic volume collapse; it’s a prolonged “good backlog, worse conversion” pattern that delays operating leverage.

The contrarian angle is that the goodwill impairment may actually be a sentiment washout event rather than a fundamental one. When a company writes down goodwill this aggressively while guiding to higher EBITDA and explicit synergy capture, the market can over-discount the balance-sheet risk and underweight the potential for a cleaner FY27 narrative if cost actions stick. The key is whether the first half of FY27 validates margin inflection; if not, the stock likely remains a value trap until leverage approaches the sub-4x target.

Key Decisions for Investors

• Long CMCO on a 6-12 month horizon only if you can tolerate integration execution risk; the setup is attractive for a mean-reversion trade if management delivers on the first ~$14M synergy tranche and leverage starts trending toward sub-4x.
• Buy CMCO calls or call spreads into weakness rather than common stock if you want upside exposure with capped downside; the stock should be most sensitive to any Q1/Q2 evidence of margin inflection and backlog conversion improvement.
• Pair trade: long CMCO / short a higher-quality industrial peer basket over 3-6 months only if you expect the market to reprice leverage reduction faster than organic growth; this is a balance-sheet normalization trade, not a secular growth trade.
• Avoid initiating a short solely on the impairment headline; the cleaner short thesis would be a failure to show sequential gross margin improvement by mid-FY27, at which point the leverage narrative can turn against the stock.
• Watch for a tactical add after any post-earnings pullback that leaves CMCO below peers on EV/EBITDA despite intact guidance; that’s the point where the stock may price in too much geopolitical and tariff risk relative to the actual earnings at risk.